81 related articles for article (PubMed ID: 17638066)
21. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
22. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
[TBL] [Abstract][Full Text] [Related]
23. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Geisler J; Detre S; Berntsen H; Ottestad L; Lindtjørn B; Dowsett M; Einstein Lønning P
Clin Cancer Res; 2001 May; 7(5):1230-6. PubMed ID: 11350888
[TBL] [Abstract][Full Text] [Related]
24. Coadministrating luteolin minimizes the side effects of the aromatase inhibitor letrozole.
Li F; Wong TY; Lin SM; Chow S; Cheung WH; Chan FL; Chen S; Leung LK
J Pharmacol Exp Ther; 2014 Nov; 351(2):270-7. PubMed ID: 25138022
[TBL] [Abstract][Full Text] [Related]
25. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
26. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Harper-Wynne C; Ross G; Sacks N; Salter J; Nasiri N; Iqbal J; A'Hern R; Dowsett M
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):614-21. PubMed ID: 12101108
[TBL] [Abstract][Full Text] [Related]
27. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
28. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
Miller WR; Larionov AA; Renshaw L; Anderson TJ; White S; Murray J; Murray E; Hampton G; Walker JR; Ho S; Krause A; Evans DB; Dixon JM
Pharmacogenet Genomics; 2007 Oct; 17(10):813-26. PubMed ID: 17885619
[TBL] [Abstract][Full Text] [Related]
29. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
Miller WR; Larionov A; Anderson TJ; Evans DB; Dixon JM
Pharmacogenomics J; 2012 Feb; 12(1):10-21. PubMed ID: 20697427
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibitors: cellular and molecular effects.
Miller WR; Anderson TJ; White S; Larionov A; Murray J; Evans D; Krause A; Dixon JM
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):83-9. PubMed ID: 16002280
[TBL] [Abstract][Full Text] [Related]
31. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Walker G; MacLeod K; Williams AR; Cameron DA; Smyth JF; Langdon SP
Gynecol Oncol; 2007 Sep; 106(3):461-8. PubMed ID: 17624412
[TBL] [Abstract][Full Text] [Related]
35. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
[TBL] [Abstract][Full Text] [Related]
36. Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Heneweer M; Muusse M; Dingemans M; de Jong PC; van den Berg M; Sanderson JT
Toxicol Sci; 2005 Feb; 83(2):257-63. PubMed ID: 15525692
[TBL] [Abstract][Full Text] [Related]
37. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
38. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
[TBL] [Abstract][Full Text] [Related]
39. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Selli C; Turnbull AK; Pearce DA; Li A; Fernando A; Wills J; Renshaw L; Thomas JS; Dixon JM; Sims AH
Breast Cancer Res; 2019 Jan; 21(1):2. PubMed ID: 30616553
[TBL] [Abstract][Full Text] [Related]
40. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]